BIOT:LSE L&G PHARMA BREAKTHROUGH GO UCITS ETF

USD 9.56 0.00 0
Icon

L&G PHARMA BREAKTHROUGH GO UCITS ETF (BIOT:LSE) Stock Analysis and Price Targets

ETF | Others | LSE
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 9.56

0.00 (0.00)%

USD 8.18M

N/A

N/A

N/A

Icon

BIOT:LSE

L&G PHARMA BREAKTHROUGH GO UCITS ETF (USD)
ETF | LSE
USD 9.56
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 8.18M

N/A

USD 9.56

L&G PHARMA BREAKTHROUGH GO UCITS ETF (BIOT:LSE) Stock Forecast

N/A

Based on the L&G PHARMA BREAKTHROUGH GO UCITS ETF stock forecast from 0 analysts, the average analyst target price for L&G PHARMA BREAKTHROUGH GO UCITS ETF is not available over the next 12 months. L&G PHARMA BREAKTHROUGH GO UCITS ETF’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of L&G PHARMA BREAKTHROUGH GO UCITS ETF is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, L&G PHARMA BREAKTHROUGH GO UCITS ETF’s stock price was USD 9.56. L&G PHARMA BREAKTHROUGH GO UCITS ETF’s stock price has changed by -2.55% over the past week, +3.28% over the past month and -15.05% over the last year.

No recent analyst target price found for L&G PHARMA BREAKTHROUGH GO UCITS ETF
No recent average analyst rating found for L&G PHARMA BREAKTHROUGH GO UCITS ETF

Company Overview L&G PHARMA BREAKTHROUGH GO UCITS ETF

NA

N/A

N/A

N/A

N/A

USD

UK

N/A

N/A

N/A

0.75 %

Adjusted Closing Price for L&G PHARMA BREAKTHROUGH GO UCITS ETF (BIOT:LSE)

Loading...

Unadjusted Closing Price for L&G PHARMA BREAKTHROUGH GO UCITS ETF (BIOT:LSE)

Loading...

Share Trading Volume for L&G PHARMA BREAKTHROUGH GO UCITS ETF Shares

Loading...

Compare Performance of L&G PHARMA BREAKTHROUGH GO UCITS ETF Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BIOT:LSE

Top Sectors

N/A

Top Regions

N/A

Valuation Growth & Performance

  • N/A

  • N/A

  • N/A

  • N/A

  • N/A

  • N/A

  • N/A

  • N/A

  • N/A

  • 0%

Stocks Similar To L&G PHARMA BREAKTHROUGH GO UCITS ETF (Sector: Others )

Symbol Name Mer Price(Change) Market Cap
XNID:LSE
Xtrackers Nifty 50 Swap UCITS .. 0.85 % 0.00 (0.00%) USD292,109.69B

ETFs Containing BIOT

Symbol Name BIOT's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About L&G PHARMA BREAKTHROUGH GO UCITS ETF (BIOT:LSE) Stock

Stock Target Advisor's fundamental analysis for L&G PHARMA BREAKTHROUGH GO UCITS ETF's stock is Very Bearish.

Unfortunately we do not have enough data on BIOT:LSE's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on BIOT:LSE's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on BIOT:LSE's stock to indicate if its overvalued.

The last closing price of BIOT:LSE's stock was USD 9.56.

The most recent market capitalization for BIOT:LSE is USD 8.18M.

Unfortunately we do not have enough analyst data on BIOT:LSE's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains L&G PHARMA BREAKTHROUGH GO UCITS ETF's stock.

Sorry, we do not have any data on the number of employees for L&G PHARMA BREAKTHROUGH GO UCITS ETF.

Sorry we do not have any infomation available on L&G PHARMA BREAKTHROUGH GO UCITS ETF's address.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...